Healthcare has no shortage of frightening statistics ... the FDA approved its first biosimilar this month when it gave Novartis' Sandoz unit the go-ahead to begin marketing its biosimilar of the top-selling cancer drug Neupogen. That approval is likely ... ..
via News Feed
via News Feed
No comments:
Post a Comment